Skip to main
NUTX

NUTX Stock Forecast & Price Target

NUTX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nutex Health is poised for continued growth with its de novo pipeline and plans to add at least 10 hospitals by 2028, driven by consolidation and partnerships in the industry, and a focus on non-Certificate of Need states. With the recent court ruling in TMA III, we expect less arbitration and a more accurate payment mechanism, leading to increased collections and a positive impact on revenue and profitability. Despite potential reimbursement cuts from government regulation, Nutex's strong track record and robust revenue stream from its hospital division contribute to a compelling valuation at 6x forward EV/EBITDA with a potential target of $306 in the near term.

Bears say

Nutex Health is a physician-led healthcare company with a negative outlook due to several factors. These include a shortage of qualified personnel, exposure to arbitration/litigation/collection, potential litigation risk, high governance and key person risk, and execution and financing risk. Additionally, Nutex's valuation seems expensive at 4x FY27 EBITDA compared to industry peers' average of 9x. Its IDR process may also be impacted by competition from other companies, and its capital-light strategy is dependent on timely and cost-effective development of new facilities and favorable market conditions for sale-leasebacks. Overall, these factors could result in missed revenue and earnings forecasts and limit the company's growth potential.

NUTX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nutex Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nutex Health Inc (NUTX) Forecast

Analysts have given NUTX a Strong Buy based on their latest research and market trends.

According to 3 analysts, NUTX has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $313.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $313.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nutex Health Inc (NUTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.